<DOC>
	<DOCNO>NCT00809549</DOCNO>
	<brief_summary>1 . Circulating bone marrow blood vessel precursor home site ischemia aid regeneration injure tissue 2 . Increasing number circulating precursor improve regeneration damage brain follow ischemic stroke .</brief_summary>
	<brief_title>Study Determine The Effect Drug Called Neupogen Stroke Recovery</brief_title>
	<detailed_description>We hypothesize mobilization bone marrow precursor cell blood stream allow redistribute injured central nervous system aid regeneration damage tissue . If hypothesis correct , predict G-CSF treatment improve functional outcome patient follow acute ischemic stroke . Underlying work follow consideration : - Currently clinical functional outcome follow ischemic stroke poor require new treatment strategy . - G-CSF administration well establish routine treatment mobilization hematopoietic endothelial precursor bone marrow circulation . - Acute ischemia locally increase factor direct circulate bone marrow derive cell home site injury . - Evidence exist bone marrow derive cell able repopulate different tissue include CNS . - Acute ischemic injury central nervous system provide milieu regeneration neural tissue .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patient 45 85 year age Patient either gender The qualify stroke ischemic total NIH Stroke Score less 18 . The stroke involve nondominant hemisphere include cerebral cortex result hemiparesis . The inclusion subcortical stroke permit size 3 cm great . Patients suffer stroke involve dominant hemisphere result mild dysphasia also eligible . The stroke classify partial anterior cerebral syndrome Oxfordshire Criteria . NIHSS baseline evaluation : *Level consciousness impair defined NIHSS 0 1 question 1a Hemiparesis define NIHSS 1 4 question 5 and/or NIHSS 1 4 question 6 . Be able start experimental treatment minimum 3 day maximum 10 day initial presentation stroke , Patient surrogate give informed consent , The patient fluent either French English . Patient hemorrhagic stroke , Patients premorbid modify Rankin score &gt; 2 ( Appendix 3b ) , Patients premorbid dementia DSMIV criterion . Patients know allergic reaction GCSF component GCSF . Patients one significant comorbidities expect limit lifespan less 12 month . Examples include limited : &gt; CHF Class II NYHA Known prior ongoing malignancy except nonmelanomatous skin cancer . Acute chronic infection ( HIV , TB , etc.. ) Other significant cardiac , renal , hepatic pulmonary dysfunction . Patients organ dysfunction would preclude test require study . Examples include limited : *Serum Cr &gt; 200 μmol/L would prevent administration contrast dye . Patients known history bone marrow dysfunction , myeloid leukemia myeloproliferative state would prevent treatment GCSF . Patients metal implant would preclude MRI examination include limited patient pacemaker , ear implant , aneurysm brain clip . Patients : history compatible thrombophilic state preexist know thrombophilic state . Patient unwilling unable comply trial requirement . Patients ongoing history illicit drug use . Female patient childbearing potential . Patients expose investigational drug last 3 month . Patients know suspected sickle cell disease , Patients splenic enlargement illness result splenic enlargement ( For example , limited myeloproliferative syndrome , hairy cell leukaemia , malaria , hepatic cirrhosis… ) , Patients ongoing history alcohol abuse , Patients know suspected history allergy intravenous contrast agent use CT scan , Patients receive chemotherapy agent within previous 5 year ( For example , limited cyclophosphamide , anthracycline , methotrexate , fluorouracil… ) Patients receive therapy within previous 5 year interfere hematopoiesis circulate blood cell ( For example , limited Lithium , Campath… . ) Patients receive cytokine within last 6 month currently receive cytokine treatment ( For example , limited Erythropoietin , Granulocyte Macrophage Colony Stimulating Factor , Keratinocyte Growth Factor , Kit Ligand… )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Stroke</keyword>
	<keyword>GCSF</keyword>
	<keyword>Hematopoeitic</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Filgrastim</keyword>
</DOC>